Renal function, revascularization and risk

Renal function, revascularization and risk.

In 1974, 14 years after the advent of regular maintenance haemodialysis, Linder et al. first reported the powerful relationship between end-stage renal failure and cardiovascular complications. This is now generally recognized, and the statistics quantifying this excess risk, such as the 100-fold increase in cardiovascular mortality associated with a requirement for chronic dialysis below the a...

Renal Function, Revascularisation and Risk

Revascularization as a treatment to improve renal function

An aging atherosclerosis-prone population has led to an increase in the prevalence of atherosclerotic renovascular disease (ARVD). Medical management of this disease, as with other atherosclerotic conditions, has improved over the past decade. Despite the widespread availability of endovascular revascularization procedures, there is inconsistent evidence of benefit in ARVD and no clear consensu...

compactifications and function spaces on weighted semigruops

chapter one is devoted to a moderate discussion on preliminaries, according to our requirements. chapter two which is based on our work in (24) is devoted introducting weighted semigroups (s, w), and studying some famous function spaces on them, especially the relations between go (s, w) and other function speces are invesigated. in fact this chapter is a complement to (32). one of the main fea...

Cystatin C, renal function, and cardiovascular risk.

Because all the patients had chronic kidney disease (CKD) (GFR <55 mL/min per 1.73 m 2 ), this study cannot be used to assert that cystatin C is definitively better than creatinine for detecting stage 3 kidney disease (GFR <60 mL/min per 1.73 m 2 ). Regarding the study methods, the authors do not mention when cystatin C was measured in the frozen samples. Were the samples measured retrospective...